New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
11:32 EDTSPRD, AZN, ARUN, NSR, PWRD, SHLD, WUBA, QIWI, DB, KERXOptions with decreasing implied volatility:
Options with decreasing implied volatility: NSR KERX WUBA ARUN DB SHLD AZN QIWI PWRD SPLS
News For NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 27, 2015
06:06 EDTSHLDSears Holdings volatility increases, shares in tight two-month price range
Subscribe for More Information
January 26, 2015
15:24 EDTAZNTeva confirms U.S. approval of AstraZeneca's Nexium generic
Subscribe for More Information
10:00 EDTARUNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:10 EDTARUNAruba Networks initiated with a Neutral at Citigroup
Subscribe for More Information
January 21, 2015
19:55 EDTKERXKeryx 9.17M share Secondary priced at $12.00
The deal size was raised to 9.17M shares from 7.2M shares. JPMorgan acted as sole book running manager for the offering.
13:38 EDTQIWIEarnings Preview: eBay shares rise over 5.5% since last earnings report
Subscribe for More Information
12:30 EDTAZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
12:12 EDTSHLDBest Buy, home retailers seen getting biggest bump from Sears demise
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
18:30 EDTKERXOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTKERXKeryx files to sell $100M in common stock
J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
12:01 EDTSHLDOverstock.com to appeal patent infringement case
Subscribe for More Information
January 16, 2015
11:04 EDTSHLDFAA proposes $533,000 civil penalty against Sears Holdings
The U.S. Department of Transportationís Federal Aviation Administration proposes a $533,000 civil penalty against Sears Holdings Management Corp. for allegedly violating Hazardous Materials Regulations. The FAA alleges that Sears on Dec. 20, 2012 offered UPS 27 boxes, each containing one DieHard Portable Power Supply that encased a non-spillable battery, for air transportation to various locations in the United States. Workers at the UPS sort facility in Louisville, Ky., discovered six of the corrosive shipments were vibrating and one was warm to the touch. The FAA alleges that Sears failed to package the batteries in accordance with the Hazardous Materials Regulations to prevent unintentional activation. The agency also alleges the shipment was not accompanied by shipping papers to indicate the hazardous nature of its contents, and was not marked or labeled. Additionally, Sears offered the shipment without providing emergency response information and failed to ensure its employees had received required hazardous materials training, the FAA alleges. Sears has 30 days from the receipt of the FAA's enforcement letter to respond to the agency.
09:09 EDTDBDeutsche Bank, Barclays lost 'tens of millions' on Swiss franc, WSJ says
Subscribe for More Information
January 15, 2015
06:42 EDTDBECB most likely will unveil bond buying program, NY Times says
The European Central Bank is "all but certain" to announce at its next meeting that it will buy government bonds, according to The New York Times. But the ECB may announce that it will buy bonds but say that it will only provide details about the program in March, some believe, the newspaper reported. Some economists contend that the initiative could be a case of "too little, too late," The Times added. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
January 14, 2015
11:15 EDTDBDeutsche Bank mulling separation of retail division, Reuters reports
Subscribe for More Information
07:37 EDTAZNJPMorgan to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction or stroke. Preliminary analysis did not reveal any unexpected safety issues. Full evaluation of the data is ongoing. The PEGASUS-TIMI 54 study investigated two different doses of ticagrelor on a background of low dose aspirin versus placebo plus low dose aspirin, in patients aged 50 and older with a history of heart attack and one additional CV risk factor. The study was designed to better understand the management of patients more than 12 months after their heart attack, who remain at high risk for major thrombotic events. Complete results from the PEGASUS-TIMI 54 study will be submitted to a scientific meeting in 2015 and pending further analysis, AstraZeneca plans to file this data with regulatory health authorities. The PEGASUS-TIMI 54 study is part of AstraZenecaís PARTHENON program. The PLATO study, involving over 18,000 ACS patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are investigating ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischaemic stroke or transient ischaemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with PAD, stroke, diabetes or atherosclerosis.
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
06:44 EDTDBTop court official backs ECB bond buying, NY Times reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use